Investors remain concerned regarding earnings growth beyond FY20E as gCopaxone competition is expected to heat up. The stock has fallen 30% in the past 12 months, despite a large generic opportunity in Revlimid.
from India Infoline News Service https://ift.tt/2qelLQc
No comments:
Post a Comment